Wedbush promotes Kelly Lisbakken to MD, investment banking

Thumbs Up At Desk

Wedbush Securities has announced the promotion of Kelly Lisbakken to Managing Director in the Healthcare Investment Banking Group.

Lisbakken is based in the firm’s San Francisco office and focuses primarily on covering biotechnology and specialty pharmaceuticals companies. is based in the firm’s San Francisco office and focuses primarily on covering biotechnology and specialty pharmaceuticals companies.

Since Lisbakken joined Pacific Growth Equities in 2004, she has completed over 130 transactions, raising over $11bn. Prior to joining Wedbush, Lisbakken worked on Cialis and the PDE4 program at ICOS Corporation (now Eli Lilly and Company). She holds a Bachelor of Arts degree in Molecular Biology from Princeton University.

'Since first joining Pacific Growth Equities and through its acquisition to become Wedbush PacGrow Healthcare, Kelly has been a key member of the investment banking team', states Scott T. Smith, Director of Healthcare Investment Banking. 'I am pleased to recognize Kelly’s achievement, and her creativity and tenacity in supporting her clients'.

The Wedbush Capital Markets group offers a wide range of products and services to corporate and institutional clients, which include equity, equity-linked and leverage financing, strategic advisory services, equity research, and market making and clearing services.

The Wedbush Investment Banking Group, a division of Capital Markets, is composed of senior, industry-focused professionals who have extensive transactional backgrounds, long-standing industry relationships, and are dedicated to playing an active role in every transaction. The group evaluates and executes complex transactions that create long-term shareholder value.

JefferiesAnd the Best Place to Work in the global financial markets 2016 is...

Register for Financial Markets News Alerts